:max_bytes(150000):strip_icc()/GettyImages-2274420688-5a9822963e8d4d7597c6f3a2d3b1c229.jpg?#)
:max_bytes(150000):strip_icc()/GettyImages-2275115310-eca1478cd1464b14bbe1e3236760ba1a.jpg?#)
Nomura initiates coverage on this recently-listed CRDMO stock, sees 18% upside despite 22% correction
Nomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positioning, diversified capabilities, and robust revenue and earnings growth projections despite recent stock correction.
Nomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positioning, diversified capabilities, and robust revenue and earnings growth projections despite recent stock correction.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
